Susquehanna International Group, LLP Vertex Pharmaceuticals Inc Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 46,048 shares of VRTX stock, worth $21.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,048

Previous 79,578 42.13%

Holding current value

$21.4 Million

Previous $37.3 Million 42.58%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $15.4 Million - $17 Million	-33,530 Reduced 42.13%	46,048 $21.4 Million
Q2 2024 Aug 15, 2024	SELL	$392.81 - $485.53 $6.05 Million - $7.48 Million	-15,402 Reduced 16.22%	79,578 $37.3 Million
Q1 2024 May 07, 2024	SELL	$407.69 - $446.08 $12.6 Million - $13.8 Million	-30,904 Reduced 24.55%	94,980 $39.7 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $25.2 Million - $30.1 Million	-73,360 Reduced 36.82%	125,884 $51.2 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $8.44 Million - $9.05 Million	24,958 Added 14.32%	199,244 $69.3 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $22.3 Million - $25 Million	-71,067 Reduced 28.97%	174,286 $61.3 Million
Q1 2023 May 16, 2023	SELL	$283.23 - $323.1 $9.53 Million - $10.9 Million	-33,648 Reduced 12.06%	245,353 $77.3 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $66.5 Million - $74.8 Million	232,658 Added 502.03%	279,001 $80.6 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $16.9 Million - $18.9 Million	-61,778 Reduced 57.14%	46,343 $13.4 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $1.24 Million - $1.54 Million	5,268 Added 5.12%	108,121 $30.5 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $51.7 Million - $60.9 Million	-233,472 Reduced 69.42%	102,853 $26.8 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $37.9 Million - $47.8 Million	-213,904 Reduced 38.88%	336,325 $73.9 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $8.47 Million - $9.48 Million	46,682 Added 9.27%	550,229 $99.8 Million
Q2 2021 Aug 11, 2021	BUY	$187.49 - $221.1 $877,640 - $1.03 Million	4,681 Added 0.94%	503,547 $102 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $51.2 Million - $59.6 Million	247,146 Added 98.18%	498,866 $107 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $48.1 Million - $64.1 Million	232,147 Added 1186.06%	251,720 $59.5 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $32.9 Million - $39 Million	-128,739 Reduced 86.8%	19,573 $5.33 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $17.6 Million - $23.1 Million	77,971 Added 110.85%	148,312 $43.1 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $9.46 Million - $11.7 Million	-47,364 Reduced 40.24%	70,341 $16.7 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $19.3 Million - $25.9 Million	115,618 Added 5539.91%	117,705 $25.8 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $2.06 Million - $2.32 Million	-12,383 Reduced 85.58%	2,087 $354,000
Q2 2019 Aug 16, 2019	BUY	$164.61 - $190.37 $1.95 Million - $2.26 Million	11,863 Added 455.04%	14,470 $2.65 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $3.44 Million - $4.09 Million	-20,981 Reduced 88.95%	2,607 $480,000
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $2.82 Million - $3.29 Million	19,340 Added 455.27%	23,588 $4.01 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $18,343 - $21,432	-121 Reduced 2.77%	4,248 $692,000
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $718,660 - $814,304	-5,235 Reduced 54.51%	4,369 $655,000
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $1.42 Million - $1.56 Million	9,604	9,604 $1.46 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Vertex Pharmaceuticals Inc Transaction History